Marmoset Canine Distemper Virus Shows Direct Primate Receptor Adaptation
A canine distemper virus strain recovered from a 2018 marmoset outbreak in Brazil has acquired the kind of receptor flexibility that virologists watch for when animal viruses begin testing new host species. In laboratory assays, the viral hemagglutinin protein from the marmoset-derived strain bound marmoset SLAM efficiently and also showed enhanced use of human SLAM, while still retaining canine SLAM usage. Two amino acid substitutions in hemagglutinin, R519I and G530S, drove that pattern.
The finding matters because SLAM is not a peripheral entry factor; for morbilliviruses, it is the gatekeeper for infection of immune cells. A virus that can use primate SLAM more effectively gains a more plausible route into lymphoid tissue, where early replication and dissemination begin. When that same adaptation extends toward human SLAM, the biological barrier separating an animal epizootic from human susceptibility becomes thinner, even if it does not disappear.
The marmoset strain did not emerge from a theoretical model. It came from a natural outbreak among free-ranging Callithrix spp. in Brazil, where lethal CDV disease had already been documented across multiple outbreaks between 2018 and 2020. In one 2018 event, five free-living black-tufted marmosets died in urban Central Brazil near neighborhoods with unvaccinated domestic dogs, a setting that makes interspecies transmission a credible concern. The study then asked a focused mechanistic question: did the marmoset virus simply circulate in primates, or had it actually adapted to primate SLAM in a way that could also affect human receptor usage?
R519I and G530S Drove Primate and Human SLAM Usage
Investigators reconstructed the hemagglutinin genes from the marmoset NHP1 strain and a dog-derived Ac96I strain, then introduced targeted mutations at positions 519 and 530. They expressed canine, marmoset, macaque, and human SLAM in Vero cells and paired those receptor systems with the viral hemagglutinin and fusion proteins to measure cell–cell fusion, a practical proxy for receptor-mediated entry. The design allowed direct comparison of receptor use across species without changing the fusion readout to suit one host over another.
The wild-type dog-derived Ac96I hemagglutinin behaved as expected for a canine virus: it used canine SLAM well, but not marmoset SLAM with the same efficiency. The marmoset-derived NHP1 hemagglutinin told a different story. It recognized canine SLAM and had also adapted to bind marmoset SLAM, indicating that primate receptor use had arisen under natural conditions rather than only in engineered systems.
A single substitution, R519I, marginally improved use of marmoset SLAM in the Ac96I background. When R519I was combined with G530S, marmoset SLAM usage increased further. Reversing those substitutions in the NHP1 background had the opposite effect: I519R or S530G reduced or abolished the enhanced primate receptor use. The same pattern appeared in quantitative fusion assays, where the signal was normalized to canine SLAM and the primate receptor gains persisted across both microscopic and reporter-based methods.
The receptor phenotype was not limited to marmoset cells. Human SLAM usage moved in the same direction as marmoset SLAM usage, with R519I enhancing human SLAM use and the R519I plus G530S combination increasing it further. In one sentence, the virus gained primate receptor compatibility without paying an obvious price in canine receptor usage.
A Primate-Adapted Lineage Without an Obvious Trade-Off
Phylogenetic analysis placed the NHP1 strain in the Europe 1/South America 1 lineage, separating it from the lineages linked to earlier macaque outbreaks. Eleven amino acid positions diverged markedly between marmoset CDVs and CDVs from other species, and the marmoset isolates carried unique mutations at or near residues previously linked to human SLAM adaptation. The receptor biology and the evolutionary signal point in the same direction: this strain was not merely a dog virus spilled into primates, but a virus that had acquired a primate-adapted entry phenotype.
The absence of a clear trade-off is especially important. In viral evolution, host adaptation often narrows fitness elsewhere, but here the hemagglutinin retained canine SLAM use while gaining stronger primate and human SLAM activity. That combination preserves the ability to circulate in the dog reservoir while extending compatibility into primate hosts, a trait set that can sustain cross-species transmission pressure over time.
CDV already has a reputation for broad host range expansion, and the virus can cause severe neurologic disease in susceptible animal hosts. In marmosets, prior outbreaks showed virus localization in lymphoid tissue, epithelial organs, and the central nervous system, a tissue distribution that likely contributes to the high mortality seen in that species. Human disease remains unproven, and the clinical consequences of CDV infection in humans are still unknown. Even so, a virus that has naturally acquired better use of human SLAM deserves attention because receptor compatibility is one of the earliest molecular hurdles in zoonotic emergence.
The study stops short of claiming imminent human risk, and that restraint is appropriate. Morbillivirus host switching requires more than SLAM adaptation; the virus must also suppress innate immunity, use nectin-4 efficiently for epithelial spread and shedding, and overcome existing immune barriers. Animal studies suggest measles immunity may provide some cross-protection against CDV, a point that keeps the current interpretation grounded rather than alarmist. Still, maintaining high measles vaccination coverage may matter in regions where SLAM-adapted CDV circulates, because partial cross-protection could become a public health buffer if exposure ever broadened.
Continued surveillance remains the practical next step. Monitoring circulating CDV strains will be essential for tracking whether these primate-adapting substitutions recur, spread, or accumulate alongside other determinants of host range. The present data show that natural CDV evolution can produce a hemagglutinin capable of stronger primate SLAM use, including human SLAM, without losing canine compatibility. That is a molecular warning sign, not a human case definition.